Sai Next Generation Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 5.01 Cr
as on 27-08-2024
- Paid Up Capital ₹ 0.10 M
as on 27-08-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 35.00 Cr
as on 27-08-2024
- Revenue 51089.10%
(FY 2023)
- Profit -222.94%
(FY 2023)
- Ebitda -1353.95%
(FY 2023)
- Net Worth 32035.60%
(FY 2023)
- Total Assets 201.83%
(FY 2023)
About Sai Next Generation Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.01 Cr and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹35.00 Cr.
Sunil Gupta, Kapil Dev, and Amrit Datta serve as directors at the Company.
- CIN/LLPIN
U74999DL2013PTC257248
- Company No.
257248
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2013
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sai Next Generation Diagnostics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Gupta  | Director | 05-Jul-2021 | Current |
| Kapil Dev | Director | 11-Sep-2021 | Current |
| Amrit Datta | Director | 05-Sep-2013 | Current |
Financial Performance and Corporate Structure Insights of Sai Next Generation Diagnostics.
Sai Next Generation Diagnostics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 51089.1% increase. The company also saw a substantial fall in profitability, with a 222.94% decrease in profit. The company's net worth Soared by an impressive increase of 32035.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sai Next Generation Diagnostics?
Unlock access to Sai Next Generation Diagnostics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Dec 2022 | ₹35.00 Cr | Open |
How Many Employees Work at Sai Next Generation Diagnostics?
Unlock and access historical data on people associated with Sai Next Generation Diagnostics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sai Next Generation Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sai Next Generation Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
